Plasma MMP-2 and MMP-7 levels are elevated first month after surgery and may promote growth of residual metastases
BACKGROUNDMMP-2 also known as gelatinase A and MMP-7 (matrilysin) are members of the zinc-dependent family of MMPs (Matrix metalloproteinase). MMP-2 and MMP-7 are remodeling enzymes that digest extracellular matrix; MMP-2 is extensively expressed during development and is upregulated at sites of tis...
Gespeichert in:
Veröffentlicht in: | World journal of gastrointestinal oncology 2021-08, Vol.13 (8), p.879-892 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 892 |
---|---|
container_issue | 8 |
container_start_page | 879 |
container_title | World journal of gastrointestinal oncology |
container_volume | 13 |
creator | Shantha Kumara, HMC Miyagaki, Hiromichi Herath, Sajith A Pettke, Erica Yan, Xiaohong Cekic, Vesna Whelan, Richard L |
description | BACKGROUNDMMP-2 also known as gelatinase A and MMP-7 (matrilysin) are members of the zinc-dependent family of MMPs (Matrix metalloproteinase). MMP-2 and MMP-7 are remodeling enzymes that digest extracellular matrix; MMP-2 is extensively expressed during development and is upregulated at sites of tissue damage, inflammation, and in stromal cells of metastatic tumors. MMP-7 is expressed in the epithelial cells and in a variety of cancers including colon tumors. Plasma MMP-2 and MMP-7 levels were assessed before and after minimally invasive colorectal resection for cancer pathology. AIMTo determine plasma MMP-2 and MMP-7 levels before and after minimally invasive colorectal resection for cancer pathology. METHODSPatients enrolled in a plasma bank for whom plasma was available were eligible. Plasma obtained from preoperative (Preop) and postoperative blood samples was used. Only colorectal cancer (CRC) patients who underwent elective minimally invasive cancer resection with preop, post-operative day (POD) 1, 3 and at least 1 late postop sample (POD 7-34) were included. Late samples were bundled into 7 d blocks (POD 7-13, 14-20, etc.) and treated as single time points. Plasma MMP-2 and MMP-7 levels were determined via enzyme-linked immunosorbent assay in duplicate. RESULTSTotal 88 minimally invasive CRC resection CRC patients were studied (right colectomy, 37%; sigmoid, 24%; and LAR/AR 18%). Cancer stages were: 1, 31%; 2, 30%; 3, 34%; and 4, 5%. Mean Preop MMP-2 plasma level (ng/mL) was 179.3 ± 40.9 (n = 88). Elevated mean levels were noted on POD1 (214.3 ± 51.2, n = 87, P < 0.001), POD3 (258.0 ± 63.9, n = 80, P < 0.001), POD7-13 (229.9 ± 62.3, n = 65, P < 0.001), POD 14-20 (234.9 ± 47.5, n = 25, P < 0.001), POD 21-27 (237.0 ± 63.5, n = 17, P < 0.001,) and POD 28-34 (255.4 ± 59.7, n = 15, P < 0.001). Mean Preop MMP-7 level was 3.9 ± 1.9 (n = 88). No significant differences were noted on POD 1 or 3, however, significantly elevated levels were noted on POD 7-13 (5.7 ± 2.5, n = 65, P < 0.001), POD 14-20 (5.9 ± 2.5, n = 25, P < 0.001), POD 21-27 (6.1 ± 3.6, n = 17, P = 0.002) and on POD 28-34 (6.8 ± 3.3, n = 15 P < 0.001,) vs preop levels. CONCLUSIONMMP-2 levels are elevated for 5 wk and MMP-7 levels elevated for weeks 2-6. The etiology of these changes in unclear, trauma and wound healing likely play a role. These changes may promote residual tumor growth and metastasis. |
doi_str_mv | 10.4251/wjgo.v13.i8.879 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8371512</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2566259556</sourcerecordid><originalsourceid>FETCH-LOGICAL-c370t-f188938adbad479dd00e9eee1ec0fed7c657e55ee889d8242c609688967e75133</originalsourceid><addsrcrecordid>eNpVkb1PwzAQxS0EohUws3pkSWrHduwsSKjiS6KiA8yWiS8lKImL7bTqf48LFQLrJL_T_e7d8BC6pCTnhaCz7cfK5RvK8lblSlZHaEorrjJREH78R0_QRQgfJD3OJaHkFE0Y50LSik2RX3Ym9AYvFsuswGaw30riDjbQBWw8YEjaRLC4aX2IuHdDfMemieBxGP0K_O57rzc7vPaudxHwyrttglyDPYTWjqbDPUQTUkE4RyeN6QJcHP4z9Hp3-zJ_yJ6e7x_nN09ZzSSJWUOVqpgy9s1YLitrCYEKACjUpAEr61JIEAIgYVYVvKhLUpWpKSVIQRk7Q9c_vuvxrQdbwxC96fTat73xO-1Mq_9PhvZdr9xGKyapoEUyuDoYePc5Qoi6b0MNXWcGcGPQhSjLQlRClAmd_aC1dyF4aH7PUKL3Yel9WDqFpVulU1jsC-QKiYw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2566259556</pqid></control><display><type>article</type><title>Plasma MMP-2 and MMP-7 levels are elevated first month after surgery and may promote growth of residual metastases</title><source>Baishideng "World Journal of" online journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Shantha Kumara, HMC ; Miyagaki, Hiromichi ; Herath, Sajith A ; Pettke, Erica ; Yan, Xiaohong ; Cekic, Vesna ; Whelan, Richard L</creator><creatorcontrib>Shantha Kumara, HMC ; Miyagaki, Hiromichi ; Herath, Sajith A ; Pettke, Erica ; Yan, Xiaohong ; Cekic, Vesna ; Whelan, Richard L</creatorcontrib><description><![CDATA[BACKGROUNDMMP-2 also known as gelatinase A and MMP-7 (matrilysin) are members of the zinc-dependent family of MMPs (Matrix metalloproteinase). MMP-2 and MMP-7 are remodeling enzymes that digest extracellular matrix; MMP-2 is extensively expressed during development and is upregulated at sites of tissue damage, inflammation, and in stromal cells of metastatic tumors. MMP-7 is expressed in the epithelial cells and in a variety of cancers including colon tumors. Plasma MMP-2 and MMP-7 levels were assessed before and after minimally invasive colorectal resection for cancer pathology. AIMTo determine plasma MMP-2 and MMP-7 levels before and after minimally invasive colorectal resection for cancer pathology. METHODSPatients enrolled in a plasma bank for whom plasma was available were eligible. Plasma obtained from preoperative (Preop) and postoperative blood samples was used. Only colorectal cancer (CRC) patients who underwent elective minimally invasive cancer resection with preop, post-operative day (POD) 1, 3 and at least 1 late postop sample (POD 7-34) were included. Late samples were bundled into 7 d blocks (POD 7-13, 14-20, etc.) and treated as single time points. Plasma MMP-2 and MMP-7 levels were determined via enzyme-linked immunosorbent assay in duplicate. RESULTSTotal 88 minimally invasive CRC resection CRC patients were studied (right colectomy, 37%; sigmoid, 24%; and LAR/AR 18%). Cancer stages were: 1, 31%; 2, 30%; 3, 34%; and 4, 5%. Mean Preop MMP-2 plasma level (ng/mL) was 179.3 ± 40.9 (n = 88). Elevated mean levels were noted on POD1 (214.3 ± 51.2, n = 87, P < 0.001), POD3 (258.0 ± 63.9, n = 80, P < 0.001), POD7-13 (229.9 ± 62.3, n = 65, P < 0.001), POD 14-20 (234.9 ± 47.5, n = 25, P < 0.001), POD 21-27 (237.0 ± 63.5, n = 17, P < 0.001,) and POD 28-34 (255.4 ± 59.7, n = 15, P < 0.001). Mean Preop MMP-7 level was 3.9 ± 1.9 (n = 88). No significant differences were noted on POD 1 or 3, however, significantly elevated levels were noted on POD 7-13 (5.7 ± 2.5, n = 65, P < 0.001), POD 14-20 (5.9 ± 2.5, n = 25, P < 0.001), POD 21-27 (6.1 ± 3.6, n = 17, P = 0.002) and on POD 28-34 (6.8 ± 3.3, n = 15 P < 0.001,) vs preop levels. CONCLUSIONMMP-2 levels are elevated for 5 wk and MMP-7 levels elevated for weeks 2-6. The etiology of these changes in unclear, trauma and wound healing likely play a role. These changes may promote residual tumor growth and metastasis.]]></description><identifier>ISSN: 1948-5204</identifier><identifier>EISSN: 1948-5204</identifier><identifier>DOI: 10.4251/wjgo.v13.i8.879</identifier><identifier>PMID: 34457193</identifier><language>eng</language><publisher>Baishideng Publishing Group Inc</publisher><subject>Basic Study</subject><ispartof>World journal of gastrointestinal oncology, 2021-08, Vol.13 (8), p.879-892</ispartof><rights>The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. 2021</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c370t-f188938adbad479dd00e9eee1ec0fed7c657e55ee889d8242c609688967e75133</citedby><cites>FETCH-LOGICAL-c370t-f188938adbad479dd00e9eee1ec0fed7c657e55ee889d8242c609688967e75133</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371512/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371512/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Shantha Kumara, HMC</creatorcontrib><creatorcontrib>Miyagaki, Hiromichi</creatorcontrib><creatorcontrib>Herath, Sajith A</creatorcontrib><creatorcontrib>Pettke, Erica</creatorcontrib><creatorcontrib>Yan, Xiaohong</creatorcontrib><creatorcontrib>Cekic, Vesna</creatorcontrib><creatorcontrib>Whelan, Richard L</creatorcontrib><title>Plasma MMP-2 and MMP-7 levels are elevated first month after surgery and may promote growth of residual metastases</title><title>World journal of gastrointestinal oncology</title><description><![CDATA[BACKGROUNDMMP-2 also known as gelatinase A and MMP-7 (matrilysin) are members of the zinc-dependent family of MMPs (Matrix metalloproteinase). MMP-2 and MMP-7 are remodeling enzymes that digest extracellular matrix; MMP-2 is extensively expressed during development and is upregulated at sites of tissue damage, inflammation, and in stromal cells of metastatic tumors. MMP-7 is expressed in the epithelial cells and in a variety of cancers including colon tumors. Plasma MMP-2 and MMP-7 levels were assessed before and after minimally invasive colorectal resection for cancer pathology. AIMTo determine plasma MMP-2 and MMP-7 levels before and after minimally invasive colorectal resection for cancer pathology. METHODSPatients enrolled in a plasma bank for whom plasma was available were eligible. Plasma obtained from preoperative (Preop) and postoperative blood samples was used. Only colorectal cancer (CRC) patients who underwent elective minimally invasive cancer resection with preop, post-operative day (POD) 1, 3 and at least 1 late postop sample (POD 7-34) were included. Late samples were bundled into 7 d blocks (POD 7-13, 14-20, etc.) and treated as single time points. Plasma MMP-2 and MMP-7 levels were determined via enzyme-linked immunosorbent assay in duplicate. RESULTSTotal 88 minimally invasive CRC resection CRC patients were studied (right colectomy, 37%; sigmoid, 24%; and LAR/AR 18%). Cancer stages were: 1, 31%; 2, 30%; 3, 34%; and 4, 5%. Mean Preop MMP-2 plasma level (ng/mL) was 179.3 ± 40.9 (n = 88). Elevated mean levels were noted on POD1 (214.3 ± 51.2, n = 87, P < 0.001), POD3 (258.0 ± 63.9, n = 80, P < 0.001), POD7-13 (229.9 ± 62.3, n = 65, P < 0.001), POD 14-20 (234.9 ± 47.5, n = 25, P < 0.001), POD 21-27 (237.0 ± 63.5, n = 17, P < 0.001,) and POD 28-34 (255.4 ± 59.7, n = 15, P < 0.001). Mean Preop MMP-7 level was 3.9 ± 1.9 (n = 88). No significant differences were noted on POD 1 or 3, however, significantly elevated levels were noted on POD 7-13 (5.7 ± 2.5, n = 65, P < 0.001), POD 14-20 (5.9 ± 2.5, n = 25, P < 0.001), POD 21-27 (6.1 ± 3.6, n = 17, P = 0.002) and on POD 28-34 (6.8 ± 3.3, n = 15 P < 0.001,) vs preop levels. CONCLUSIONMMP-2 levels are elevated for 5 wk and MMP-7 levels elevated for weeks 2-6. The etiology of these changes in unclear, trauma and wound healing likely play a role. These changes may promote residual tumor growth and metastasis.]]></description><subject>Basic Study</subject><issn>1948-5204</issn><issn>1948-5204</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpVkb1PwzAQxS0EohUws3pkSWrHduwsSKjiS6KiA8yWiS8lKImL7bTqf48LFQLrJL_T_e7d8BC6pCTnhaCz7cfK5RvK8lblSlZHaEorrjJREH78R0_QRQgfJD3OJaHkFE0Y50LSik2RX3Ym9AYvFsuswGaw30riDjbQBWw8YEjaRLC4aX2IuHdDfMemieBxGP0K_O57rzc7vPaudxHwyrttglyDPYTWjqbDPUQTUkE4RyeN6QJcHP4z9Hp3-zJ_yJ6e7x_nN09ZzSSJWUOVqpgy9s1YLitrCYEKACjUpAEr61JIEAIgYVYVvKhLUpWpKSVIQRk7Q9c_vuvxrQdbwxC96fTat73xO-1Mq_9PhvZdr9xGKyapoEUyuDoYePc5Qoi6b0MNXWcGcGPQhSjLQlRClAmd_aC1dyF4aH7PUKL3Yel9WDqFpVulU1jsC-QKiYw</recordid><startdate>20210815</startdate><enddate>20210815</enddate><creator>Shantha Kumara, HMC</creator><creator>Miyagaki, Hiromichi</creator><creator>Herath, Sajith A</creator><creator>Pettke, Erica</creator><creator>Yan, Xiaohong</creator><creator>Cekic, Vesna</creator><creator>Whelan, Richard L</creator><general>Baishideng Publishing Group Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210815</creationdate><title>Plasma MMP-2 and MMP-7 levels are elevated first month after surgery and may promote growth of residual metastases</title><author>Shantha Kumara, HMC ; Miyagaki, Hiromichi ; Herath, Sajith A ; Pettke, Erica ; Yan, Xiaohong ; Cekic, Vesna ; Whelan, Richard L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c370t-f188938adbad479dd00e9eee1ec0fed7c657e55ee889d8242c609688967e75133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Basic Study</topic><toplevel>online_resources</toplevel><creatorcontrib>Shantha Kumara, HMC</creatorcontrib><creatorcontrib>Miyagaki, Hiromichi</creatorcontrib><creatorcontrib>Herath, Sajith A</creatorcontrib><creatorcontrib>Pettke, Erica</creatorcontrib><creatorcontrib>Yan, Xiaohong</creatorcontrib><creatorcontrib>Cekic, Vesna</creatorcontrib><creatorcontrib>Whelan, Richard L</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of gastrointestinal oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shantha Kumara, HMC</au><au>Miyagaki, Hiromichi</au><au>Herath, Sajith A</au><au>Pettke, Erica</au><au>Yan, Xiaohong</au><au>Cekic, Vesna</au><au>Whelan, Richard L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma MMP-2 and MMP-7 levels are elevated first month after surgery and may promote growth of residual metastases</atitle><jtitle>World journal of gastrointestinal oncology</jtitle><date>2021-08-15</date><risdate>2021</risdate><volume>13</volume><issue>8</issue><spage>879</spage><epage>892</epage><pages>879-892</pages><issn>1948-5204</issn><eissn>1948-5204</eissn><abstract><![CDATA[BACKGROUNDMMP-2 also known as gelatinase A and MMP-7 (matrilysin) are members of the zinc-dependent family of MMPs (Matrix metalloproteinase). MMP-2 and MMP-7 are remodeling enzymes that digest extracellular matrix; MMP-2 is extensively expressed during development and is upregulated at sites of tissue damage, inflammation, and in stromal cells of metastatic tumors. MMP-7 is expressed in the epithelial cells and in a variety of cancers including colon tumors. Plasma MMP-2 and MMP-7 levels were assessed before and after minimally invasive colorectal resection for cancer pathology. AIMTo determine plasma MMP-2 and MMP-7 levels before and after minimally invasive colorectal resection for cancer pathology. METHODSPatients enrolled in a plasma bank for whom plasma was available were eligible. Plasma obtained from preoperative (Preop) and postoperative blood samples was used. Only colorectal cancer (CRC) patients who underwent elective minimally invasive cancer resection with preop, post-operative day (POD) 1, 3 and at least 1 late postop sample (POD 7-34) were included. Late samples were bundled into 7 d blocks (POD 7-13, 14-20, etc.) and treated as single time points. Plasma MMP-2 and MMP-7 levels were determined via enzyme-linked immunosorbent assay in duplicate. RESULTSTotal 88 minimally invasive CRC resection CRC patients were studied (right colectomy, 37%; sigmoid, 24%; and LAR/AR 18%). Cancer stages were: 1, 31%; 2, 30%; 3, 34%; and 4, 5%. Mean Preop MMP-2 plasma level (ng/mL) was 179.3 ± 40.9 (n = 88). Elevated mean levels were noted on POD1 (214.3 ± 51.2, n = 87, P < 0.001), POD3 (258.0 ± 63.9, n = 80, P < 0.001), POD7-13 (229.9 ± 62.3, n = 65, P < 0.001), POD 14-20 (234.9 ± 47.5, n = 25, P < 0.001), POD 21-27 (237.0 ± 63.5, n = 17, P < 0.001,) and POD 28-34 (255.4 ± 59.7, n = 15, P < 0.001). Mean Preop MMP-7 level was 3.9 ± 1.9 (n = 88). No significant differences were noted on POD 1 or 3, however, significantly elevated levels were noted on POD 7-13 (5.7 ± 2.5, n = 65, P < 0.001), POD 14-20 (5.9 ± 2.5, n = 25, P < 0.001), POD 21-27 (6.1 ± 3.6, n = 17, P = 0.002) and on POD 28-34 (6.8 ± 3.3, n = 15 P < 0.001,) vs preop levels. CONCLUSIONMMP-2 levels are elevated for 5 wk and MMP-7 levels elevated for weeks 2-6. The etiology of these changes in unclear, trauma and wound healing likely play a role. These changes may promote residual tumor growth and metastasis.]]></abstract><pub>Baishideng Publishing Group Inc</pub><pmid>34457193</pmid><doi>10.4251/wjgo.v13.i8.879</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1948-5204 |
ispartof | World journal of gastrointestinal oncology, 2021-08, Vol.13 (8), p.879-892 |
issn | 1948-5204 1948-5204 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8371512 |
source | Baishideng "World Journal of" online journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
subjects | Basic Study |
title | Plasma MMP-2 and MMP-7 levels are elevated first month after surgery and may promote growth of residual metastases |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T09%3A55%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20MMP-2%20and%20MMP-7%20levels%20are%20elevated%20first%20month%20after%20surgery%20and%20may%20promote%20growth%20of%20residual%20metastases&rft.jtitle=World%20journal%20of%20gastrointestinal%20oncology&rft.au=Shantha%20Kumara,%20HMC&rft.date=2021-08-15&rft.volume=13&rft.issue=8&rft.spage=879&rft.epage=892&rft.pages=879-892&rft.issn=1948-5204&rft.eissn=1948-5204&rft_id=info:doi/10.4251/wjgo.v13.i8.879&rft_dat=%3Cproquest_pubme%3E2566259556%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2566259556&rft_id=info:pmid/34457193&rfr_iscdi=true |